Drug intelligence / Profile preview

SBT-580

Development stage: Preclinical
Lead developer: Stealth BioTherapeutics
Modality: Small Molecules

Overview

SBT-580 is a series of novel small-molecule mitochondrial modulators being developed by Stealth BioTherapeutics. The lead compound in this series is SBT-589. These compounds are designed to improve mitochondrial function by targeting unspecified mitochondrial pathways. The program is currently in the preclinical stage, with primary development efforts focused on treating Friedreich's ataxia (FA) cardiomyopathy and various neurological indications.

Beyond the preview

Go deeper on SBT-580.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-580.

Explore the full profile